Clinical Trial Update: QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating QLC5513 alone or with QL1706 for previously treated advanced or metastatic triple-negative breast cancer is not yet recruiting, spons…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• QL1706
• QLC5513

Snippet

Sponsor: Fudan University | Conditions: Triple-negative Breast Cancer (TNBC) | Phase 2 | Status: NOT_YET_RECRUITING